FDA grants breakthrough status to Cidara’s flu drug Cidara Therapeutics' CD388, a long-acting influenza prophylactic, has previously received funding worth up to $339 million from the US BARDA.

The US FDA granted the drug Breakthrough Therapy designation to Cidara Therapeutics’ its investigational influenza prophylactic, CD388, for the prevention of influenza A and B in high-risk adults and adolescents.

#News #FluTherapy #CD388

FDA grants breakthrough status to Cidara’s flu drug Cidara Therapeutics' CD388, a long-acting influenza prophylactic, has previously received funding worth up to $339 million from the US BARDA.

The US FDA granted the drug Breakthrough Therapy designation to Cidara Therapeutics’ its investigational influenza prophylactic, CD388, for the prevention of influenza A and B in high-risk adults and adolescents.

#News #FluTherapy #CD388